Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyeloMATCH Master Screening and Reassessment Protocol
NCT05564390Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- May 2029
- Modality
- Irreversible Covalent Inhibitors, Antibody-Drug Conjugates (ADCs), Targeted Protein Degraders (TPDs)
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of venetoclax, inqovi, enasidenib, luspatercept, emavusertib and 5 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (41 arms), sponsored by National Cancer Institute. Primary endpoint: Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment. Started Jun 2024; status: recruiting.
02
Drugs
venetoclaxinqovienasidenibluspaterceptemavusertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05564390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564390.